Latest / Applied Clinical Trials
ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research
In today’s ACT Brief, we explore how real-world data can improve protocol design and feasibility, highlight new findings from Novo Nordisk’s oral semaglutide program, and review Eli Lilly’s promising Phase II results for a novel amylin receptor agonist.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.